PDX INSIGHTS
PIONEERING CANCER RESEARCH
Model Details

Patient Information for Model: HCI-038

Model Contact
Model: HCI-038
Model Contact: Alana Welm
Institution: HCI Breast PDX Program
Email: Alana.Welm@hci.utah.edu

Patient Information
Clinical Timeline

Color Keys:
 
 Positive
 
 Negative
 
 N/A

Clinical Information at Collection
Clinical Biomarkers/Mutations at Collection
Pathology Information at Collection

Model Information for Model: HCI-038

Model Details - Initial Implantation of Patient Tissue
Biomarkers & Mutations
Model Details - Acceptable Conditions for Passaging
Mutations (Cancer Gene Census List)
Mutation data is currently not available.

CNV
There are no omics data for this model.


Drug Studies for Model: HCI-038

Treatment Response Across All Studies
CR <=-95% to -100% PR <-30% to >-95% SD >=-30% to +20% PD >=+20% NA
Study Metadata
Study Design
Treatment Results





Histology Information for Model: HCI-038
There are no histology images for this model.













Metastasis Information for Model: HCI-038
 
Patient
PDX
Abdomen
Adrenal gland
Bone
Bone (de novo)
Bones
Brain
CTC
Chest
Chest wall
Contralateral Breast
Dura
Fallopian Tubes
Head
Kidney
LMD
Liver
Lung
Lymph node
Lymph nodes
Neck
None
Ovary
Pancreas
Pericardium
Peritoneal cavity
Peritoneum
Pleura
Pleural effusion
Shoulder
Skin
Spine
Spleen
Thoracic Spine
Thymus
medistinal and right hilar

Patient Treatment Information for Model: HCI-038

Event IdTreatmentTreatment SettingAge at StartAge at EndDuration
11Lumpectomy Neoadjuvant49.0849.1629 days
12Radiation with boostNeoadjuvant49.2549.591 days
15TamoxifenNeoadjuvant53.555.6767 days
18Taxol/carboplatin Neoadjuvant60.560.7591 days
21XelodaNeoadjuvant61.561.5933 days
22Genetic testing CHEK2 VUS: p.G342SNeoadjuvant61.661.6829 days
23GabapentinNeoadjuvant61.761.7518 days
31Radiation TherapyAdjuvant62.0862.1629 days













Please wait...